Treatment of HIV infection with raltegravir

Bibliography

• CDC. HIV Prevalence Estimates. MMWR 2008;57:1073-6
   PubMedGoogle Scholar
• Hall H, Song R, Rhodes P, et al. Estimation of HIV Incidence in the United States. JAMA 2008;300(5):520-9
   PubMed Web of Science ®Google Scholar
• UNAIDS, 2008. Available at: www.unaids.org. [Last accessed 24 Dec 2008]
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008:1-139. Available at: https://www.aidsinfo.nih.gov [Last accessed 5 November 2008]
   Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, CD4+ Count-Guided Interruption of Antiretroviral Treatment. N Engl J Med 2006;355:2283-96
   PubMed Web of Science ®Google Scholar
• Iaccino E, Schiavone M, Fiume G, et al. The aftermath of the Merck HIV Vaccine trial. Retrovirology 2008;5:56-62
   PubMed Web of Science ®Google Scholar
• Dyda F, Hickman AB, Jenkins TM, et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994;266:1981-6
   PubMed Web of Science ®Google Scholar
• Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004;4:965-77
   PubMed Web of Science ®Google Scholar
• Semenova E, Marchand C, Pommier Y. HIV-1 integrase inhibitors: update and perspectives. Adv Pharmacol 2008;56:199-228
   PubMedGoogle Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50
   PubMed Web of Science ®Google Scholar
• Morrison SA, Steigbigel RT. A promising new therapy for HIV infection – integrase inhibitor. US Infectious Disease 2007;2:13-16
   Google Scholar
• Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000;97:11244-9
   PubMed Web of Science ®Google Scholar
• Pandey KK, Bera S, Zahm J, et al. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol 2007;81:12189-99
   PubMed Web of Science ®Google Scholar
• Savarino A. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007;4:21-36
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-9
   PubMed Web of Science ®Google Scholar
• Isentress [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2007
   Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
   PubMed Web of Science ®Google Scholar
• Andrews E, Glue P, Labadie P, et al. A pharmacokinetic study to evaluate an interaction between maraviroc and raltegravir in healthy adults [abstract H-4055]. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, 25 – 29 October 2008, Washington, DC, USA
   Google Scholar
• Wenning LA, Hwang E, Nguyen B-Y, et al. Pharmacokinetic/pharmacodynamic analyses for raltegravir in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treatment [abstract H-4054]. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, 25 – 29 October 2008, Washington, DC, USA
   Google Scholar
• Markowitz M, Morales-ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-15
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr 2007;46:125-32
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naïve HIV-1 infected patients: 96-week data [Abstract TUAB0102]. Program and abstracts of the 17th International AIDS Conference; 3 – 8 August, Mexico City, Mexico
   Google Scholar
• Lennox J, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive HIV-1 infected patients: STARTMRK Protocol 021 [Abstract H-896a]. Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting, 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Cooper D, Steigbigel R, Gatell J, et al. Subgroup analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65
   PubMed Web of Science ®Google Scholar
• Grinzstejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 2007;369:1261-69
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Eron JE, et al. 96-week results from BENCHMRK 1&2, Phase III studies of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV [Abstract K-103. Poster #571]. Conference on Retroviruses and Opportunistic Infections; February 2009, Montreal, Canada
   Google Scholar
• Towner W, Klein D, Follansbee S, et al. Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen [Abstract TUPE0115]. Program and abstracts of the 17th International AIDS Conference; 3 – 8 August 2008, Mexico City, Mexico
   Google Scholar
• Mugavero M, Lin H, Willig G, et al. The impact of darunavir / ritonavir and raltegravir in the clinic: a new era for treatment-experienced patients? [Abstract H-1262]. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, 25 – 29 October 2008, Washington DC, USA
   Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial [Abstract THAB0406]. Program and abstracts of the 17th International AIDS Conference; 3 – 8 August 2008, Mexico City, Mexico
   Google Scholar
• Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. [Abstract 70aLB]. 16th Conference on Retroviruses and Opportunistic Infections, 8 – 11 February 2009, Montreal, Canada
   Google Scholar
• Cooper DA, Steigbigel RT, Lennox J, et al. Review of cancer incidence in raltegravir clinical trials [Abstract R-106]. 16th Conference on Retroviruses and Opportunistic Infections, 8 – 11 February 2009, Montreal, Canada
   Google Scholar
• Eron JE, Nguyen BY, Steigbigel RT, et al. AIDS defining conditions in the BENCHMRK-1 and -2 trials: 48-week analysis. [Abstract H-1249]. 48th Annual ICAAC/IDSA 46th Meeting, 25-29 October 2008, Washington, DC, USA
   Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of Drug Resistance Mutations in HIV-1. Topics in HIV Medicine 2008;16(5):138-145
   PubMedGoogle Scholar
• Fransen S, Danovich R, Ke Y, et al. Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways [Abstract 7]. Program and abstracts of the XVII International HIV Drug Resistance Workshop. Sitges, Spain. June 10-14, 2008
   Google Scholar
• Witmer M, Danovich R, Dar A, et al. Cross resistance between HIV-1 integrase strand transfer inhibitors (InSTIs) raltegravir, elvitegravir, and second generation InSTIs [Abstract H-1232]. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, 25 – 29 October 2008, Washington, DC, USA
   Google Scholar